Pathogenic involvement of heregulin-β 1 in anti-atherogenesis

Regulatory Peptides

Volumn 175, Issue 1-3, 2012, Pages 11-14

  Watanabe, Takuya ^a   Sato, Kengo ^a   Itoh, Fumiko ^a   Iso, Yoshitaka ^b  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Atherosclerosis; Heregulin 1; Macrophage; Restenosis; Vascular smooth muscle cell

Indexed keywords

GELATINASE B; HEREGULIN BETA 1; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEU DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIATHEROGENESIS; ANTIATHEROSCLEROTIC EFFECT; CAROTID ATHEROSCLEROSIS; CHRONIC DRUG ADMINISTRATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HEART PROTECTION; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; MICE; NEUREGULIN-1; RATS;

ANIMALIA; MUS; RATTUS;

EID: 84862777623     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.01.004     Document Type: Review

References (45)

1. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007, 190:1-65.
2. Gumà A., Martínez-Redondo V., López-Soldado I., Cantó C., Zorzano A. Emerging role of neuregulin as a modulator of muscle metabolism. Am J Physiol Endocrinol Metab 2010, 298:E742-E750.
3. Lemke G. Neuregulins in development. Mol Cell Neurosci 1996, 7:247-262.
4. erbB-4. EMBO J 1994, 13:3517-3523.
5. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003, 284:14-30.
6. Wen D., Peles E., Cupples R., Suggs S.V., Bacus S.S., Luo Y., et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992, 69:559-572.
7. Holmes W.E., Sliwkowski M.X., Akita R.W., Henzel W.J., Lee J., Park J.W., et al. Identification of heregulin, a specific activator of p185erbB2. Science 1992, 256:1205-1210.
8. Marchionni M.A., Goodearl A.D., Chen M.S., Bermingham-McDonogh O., Kirk C., Hendricks M., et al. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 1993, 362:312-318.
9. Falls D.L., Rosen K.M., Corfas G., Lane W.S., Fischbach G.D. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 1993, 72:801-815.
10. Ho W.H., Armanini M.P., Nuijens A., Phillips H.S., Osheroff P.L. Sensory and motor neuron-derived factor. A novel heregulin variant highly expressed in sensory and motor neurons. J Biol Chem 1995, 270:14523-14532.
11. Lemmens K., Doggen K., De Keulenaer G.W. Role of neuregulin-1/erbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007, 116:954-960.
12. Xu Y., Li X., Zhou M. Neuregulin-1/ErbB signaling: a druggable target for treating heart failure. Curr Opin Pharmacol 2009, 9:214-219.
13. Oksala N., Levula M., Airla N., Pelto-Huikko M., Ortiz R.M., Järvinen O., et al. ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries-Tampere vascular study. Ann Med 2009, 41:279-290.
14. Shirakabe K., Wakatsuki S., Kurisaki T., Fujisawa-Sehara A. Roles of Meltrin β/ADAM19 in the processing of neuregulin. J Biol Chem 2001, 276:9352-9358.
15. Jiang Z., Zhou M. Neuregulin signaling and heart failure. Curr Heart Fail Rep 2010, 7:42-47.
16. Sawyer D.B., Caggiano A. Neuregulin-1β for the treatment of systolic heart failure. J Mol Cell Cardiol 2011, 51:501-505.
17. Liu X., Gu X., Li Z., Li X., Li H., Chang J., et al. Neuregulin-1/erB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006, 48:1438-1447.
18. Gu X., Liu X., Xu D., Li X., Yan M., Qi Y., et al. Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. Cardiovasc Res 2010, 88:334-343.
19. Jabbour A., Hayward C.S., Keogh A.M., Kotlyar E., McCrohon J.A., England J.F., et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 2011, 13:83-92.
20. Gao R., Zhang J., Cheng L., Wu X., Dong W., Yang X., et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 2010, 55:1907-1914.
21. Ky B., Kimmel S.E., Safa R.N., Putt M.E., Sweitzer N.K., Fang J.C., et al. Neuregulin-1β is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009, 120:310-317.
22. Iivanainen E., Paatero I., Heikkinen S.M., Junttila T.T., Cao R., Klint P., et al. Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 2007, 313:2896-2909.
23. Kalinowski A., Plowes N.J., Huang Q., Berdejo-Izquierdo C., Russell R.R., Russell K.S. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J 2010, 24:2567-2575.
24. Panutsopulos D., Arvanitis D.L., Tsatsanis C., Papalambros E., Sigala F., Spandidos D.A. Expression of heregulin in human coronary atherosclerotic lesions. J Vasc Res 2005, 42:463-474.
25. Russell K.S., Stern D.F., Polverini P.J., Bender J.R. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol Heart Circ Physiol 1999, 46:H2205-H2211.
26. Hedhli N., Russell K.S. Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis. Curr Hypertens Rep 2010, 12:411-417.
27. Safa R.N., Peng X.Y., Pentassuglia L., Lim C.C., Lamparter M., Silverstein C., et al. Neuregulin-1β regulation of embryonic endothelial progenitor cell survival. Am J Physiol Heart Circ Physiol 2011, 300:H1311-H1319.
28. Amin D.N., Hida K., Bielenberg D.R., Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not erbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006, 66:2173-2180.
29. Mograbi B., Rochet N., Imbert V., Bourget I., Bocciardi R., Emiliozzi C., et al. Human monocytes express amphiregulin and heregulin growth factors upon activation. Eur Cytokine Netw 1997, 8:73-81.
30. 1 on macrophage foam cell formation and atherosclerosis. Circ Res 2009, 105:500-510.
31. Xu Z., Ford G.D., Croslan D.R., Jiang J., Gates A., Allen R., et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis 2005, 19:461-470.
32. Jiao L., Wang M.C., Yang Y.A., Chen E.Q., Xu H.T., Wu K.Y., et al. Norepinephrine reversibly regulates the proliferation and phenotypic transformation of vascular smooth muscle cells. Exp Mol Pathol 2008, 85:196-200.
33. Clement C.M., Thomas L.R., Mou Y., Croslan D.R., Gibbons G.H., Ford B.D. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J Vasc Res 2007, 44:303-312.
34. Timolati F., Ott D., Pentassuglia L., Giraud M.N., Perriard J.C., Suter T.M., et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 2006, 41:845-854.
35. Hedhli N., Huang Q., Kalinowski A., Palmeri M., Hu X., Russell R.R., et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 2011, 123:2254-2262.
36. Brero A., Ramella R., Fitou A., Dati C., Alloatti G., Gallo M.P., et al. Neuregulin-1β1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res 2010, 88:443-452.
37. Li Q., Zhang R., Ge Y., Mei Y., Guo Y. Effects of neuregulin on expression of MMP-9 and NSE in brain of ischemia/reperfusion rat. J Mol Neurosci 2009, 38:207-215.
38. Li B., Zheng Z., Wei Y., Wang M., Peng J., Kang T., et al. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol 2011, 10:69.
39. Cote G.M., Miller T.A., Lebrasseur N.K., Kuramochi Y., Sawyer D.B. Neuregulin-1α and β isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 2005, 311:135-146.
40. Okoshi K., Nakayama M., Yan X., Okoshi M.P., Schuldt A.J., Marchionni M.A., et al. Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of β-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation 2004, 110:713-717.
41. Lemmens K., Fransen P., Sys S.U., Brutsaert D.L., De Keulenaer G.W. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 2004, 109:324-326.
42. Matsukawa R., Hirooka Y., Nishihara M., Ito K., Sunagawa K. Neuregulin-1/ErbB signaling in rostral ventrolateral medulla is involved in blood pressure regulation as an antihypertensive system. J Hypertens 2011, 29:1735-1742.
43. Shyu W.C., Lin S.Z., Chiang M.F., Yang H., Thajeb P., Li H. Neuregulin-1 reduces ischemia-induced brain damage in rats. Neurobiol Aging 2004, 25:935-944.
44. Hintsanen M., Elovainio M., Puttonen S., Kivimäki M., Raitakari O.T., Lehtimäki T., et al. Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men. Ann Behav Med 2007, 33:148-155.
45. Service H.M., Hintsanen M., Hintsa T., Lehtimäki T., Raitakari O.T., Viikari J.S., et al. Does neuregulin-1 play a role in Type A behavior? The cardiovascular risk in young Finns study. Behav Brain Funct 2008, 4:40.